In response to growing public concern over rising drug costs, U.S. policymakers have proposed a Most-Favored-Nation (MFN) pricing model, linking domestic drug prices to those negotiated in other developed countries, many of which operate under tightly regulated single-payer systems.
While the MFN model is framed as a cost-saving solution, its ripple effects could be far-reaching. From potential disruptions to global access and affordability, to unintended consequences for medical innovation and launch strategies, the proposal raises critical questions about sustainability and equity.
Could a policy designed to lower prices at home end up destabilizing pharmaceutical systems abroad?
Download the PDF to explore the full POV and uncover the risks, trade-offs and alternative strategies that could shape a more balanced and forward-looking approach to drug pricing.
Author
Heather Miller joined EVERSANA in 2024 as a Principal Analyst, bringing nearly a decade of specialized experience in pharmaceutical pricing strategy and compliance. Prior to joining EVERSANA, Heather spent eight years working with multiple…